Search
Login
Register
Menu
BJH
Home
News
Newsroom
Links
CongressUpdate
Guidelines
Specials
Hematotrials
Patients
All
All
BJH articles
Blog articles
Specials
Search
Forgot Password?
Not a member yet? Register here
Home
/
General
/ Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’
“Article: Highlights in urologic cancer” has been added to your cart.
View cart
Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’
€
2.42
Article: Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’ quantity
Add to cart
SKU:
product-article-11182
Category:
General
Description
Description
Rebuttal to ‘The COMPARZ study presented at ESMO 2012: how pliable is non-inferiority?’
Related products
Article: Highlights in genitourinary cancers
€
2.42
Add to cart
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€
2.42
Add to cart
1 year subscription print edition of the Belgian Journal of Hematology (BJH)
€
147.15
Add to cart
Article: Highlights in respiratory oncology
€
2.42
Add to cart